for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up
Healthcare

BRIEF-Almirall: EMA Accepts Filing Of Marketing Authorization Application For Drug To Treat Actinic Keratosis

March 2 (Reuters) - Almirall SA:

* SAYS EMA ACCEPTANCE FOR FILING OF MARKETING AUTHORIZATION APPLICATION (MAA) FOR TIRBANIBULIN IN ACTINIC KERATOSIS

* IT IS ESTIMATED THAT PEAK SALES OF TIRBANIBULIN WILL BE IN EXCESS OF 250 MILLION EUROS IN EUROPE AND IN THE US Source text: bit.ly/39fhDo1 Further company coverage: (Gdansk Newsroom)

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up